Julie Kerckhof

Daniel Andrade da Cunha, PhD, is Research Director at Flen Health and a molecular and cellular biologist with more than 20 years of experience spanning academia and the biopharmaceutical industry. He has led multidisciplinary research teams in drug discovery, target identification, assay development, and biomarker strategy across therapeutic areas including wound healing, oncology, and diabetes. Dr. Andrade da Cunha has authored 45 peer-reviewed publications and has been awarded five national and international research grants.

Julie Kerckhof is US Business Strategy Director at Flen Health, where she leads the company’s strategic activities related to the US market. With a background in finance and business, she began her career in banking before joining Flen Health in 2015.
Throughout her career at Flen Health, Julie has led multidisciplinary teams across departments and contributed to the company’s growth through roles spanning finance, marketing leadership, and strategic business development. In her current role, she is responsible for advancing the US project, aligning internal teams around key priorities, and supporting the execution of Flen Health’s long-term ambitions.

Dr. Slade is a dual board-certified subspecialist in pediatrics and clinical immunology with more than 30 years of industry-based experience in clinical research and drug development, having >100 peer-reviewed publications to date with >2,500 citations. He has directed >300 clinical trials of drugs, biologics and devices.
After holding academic appointments at the University of Michigan and Cornell University Medical Center, he left academia in 1989 to work with Jonas Salk, MD, on an HIV therapeutic vaccine joint venture, taking the position of Director of AIDS and Immunology at Rhône-Poulenc Rorer (now Sanofi-Aventis).
In 1994, he joined 3M Pharmaceuticals as Chief Medical Officer, overseeing a global clinical research staff of 200 people located in US, EU, Latin America, Japan, Australia, New Zealand and South Africa. Product development spanned a range of disease targets and pharmacologic approaches, including a groundbreaking new class of immune response modifiers for viral infections and cancer. Dr. Slade joined Healthpoint in 2006 to develop clinical research capabilities in advance of moving the business into the biotherapeutics arena, and subsequently served as CMO and VP of R&D for Smith & Nephew’s Advanced Wound Management division.
Since 2017 Dr. Slade has provided consulting services in clinical development to a range of large and small pharmaceutical, biopharmaceutical and tissue based companies. Dr. Slade served on the Board of Directors and as treasurer of the Wound Healing Society for seven years. Dr. Slade earned his undergraduate degree in biology from Hamilton College in Clinton, N.Y., followed by his medical degree from State University of New York (SUNY) Upstate Medical University in Syracuse, N.Y. He completed his pediatrics residency training at C.S. Mott Children’s Hospital in Ann Arbor, Michigan, followed by a fellowship in clinical immunology at the University of Michigan.

Georgios Theocharidis, PhD, is an Assistant Professor of Surgery at Harvard Medical School and Principal Investigator at the Rongxiang Xu, MD, Center for Regenerative Therapeutics at Beth Israel Deaconess Medical Center. With multidisciplinary training spanning computer engineering, biomedical engineering, and cell biology, his research focuses on understanding the cellular and molecular mechanisms underlying impaired diabetic wound healing and translating these discoveries into new regenerative therapies. His laboratory integrates single-cell and spatial multi-omics with preclinical models to define the immune-stromal-epithelial-endothelial interactions that distinguish healing from non-healing diabetic wounds. His work further leverages bioengineering approaches to therapeutically reprogram the wound microenvironment, including engineered cell therapies, localized cytokine delivery, mRNA therapeutics, and pharmacological modulation of inflammatory pathways.